Researchers unveiled NEO‑STIM, a platform that refines neoantigen‑specific adoptive T‑cell therapy by improving selection and stimulation of patient‑specific tumor antigens. The technology—described in Nature Communications—integrates antigen discovery, T‑cell expansion protocols, and phenotypic screening to enhance the yield and functionality of tumor‑reactive T cells for individualized treatment. Neoantigen T‑cell therapy targets tumor‑specific mutations unique to a patient; NEO‑STIM aims to accelerate manufacturing and increase the fraction of high‑avidity T‑cells, which could improve response rates in solid tumors. The team reported preclinical validation and early translational prospects for moving toward clinical testing.